肝癌患者射频消融术后使用索拉非尼：一项初步研究。

Sorafenib after RFA in HCC patients: a pilot study.

作者信息

de Stefano Giorgio, Farella Nunzia, Scognamiglio Umberto, Liorre Giulia, Calabria Giosuele, Ascione Tiziana, Giorgio Antonio, Iodice Valentina

出版信息

Hepatogastroenterology. 2015 Mar-Apr;62(138):261-3.

PMID:25916044

Abstract

BACKGROUND/AIMS: To investigate the effectiveness and safety of sorafenib after radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC).

METHODOLOGY

44 intermediate or advanced HCC patients received sorafenib treatment after debulking with RFA therapy. Time to progression (TTP), response rate (RR), duration of sorafenib treatment and adverse effects were evaluated. An explorative comparison was performed with patients treated with sorafenib only.

RESULTS

At 12 months, TTP was 10.3 months (range: 1-32). RR was 61% with 2 complete responses, and duration of sorafenib therapy was 10.9 months (1-32). No new safety concerns were report-ed. With sorafenib only, TTP was 7.2 months (range: 0-38) and RR was 40%, with one complete response; duration of therapy was 7.3 months (0-38).

CONCLUSIONS

The sequence of RFA and sorafenib appears effective and safe in HCC patients. These findings could support the use of a sequential treatment with RFA and sorafenib in HCC patients.

摘要

背景/目的：探讨索拉非尼在肝细胞癌（HCC）患者射频消融（RFA）后应用的有效性和安全性。

方法

44例中晚期HCC患者在接受RFA减瘤治疗后接受索拉非尼治疗。评估疾病进展时间（TTP）、缓解率（RR）、索拉非尼治疗持续时间及不良反应。对仅接受索拉非尼治疗的患者进行探索性比较。

结果

12个月时，TTP为10.3个月（范围：1 - 32个月）。RR为61%，有2例完全缓解，索拉非尼治疗持续时间为10.9个月（1 - 32个月）。未报告新的安全问题。仅使用索拉非尼时，TTP为7.2个月（范围：0 - 38个月），RR为40%，有1例完全缓解；治疗持续时间为7.3个月（0 - 38个月）。